Sales & Earnings In Brief
This article was originally published in The Tan Sheet
P&G struggles with developed market hump; divested Pfizer Nutrition grows 18% in Q2; Teva heralds PGT Healthcare’s Vicks launch in Poland and Russia; Ganeden, Airborne deals lift Schiff Nutrition’s fiscal 2012; more Sales & Earnings In Brief.
You may also be interested in...
Changes may be ahead for Procter & Gamble following William Ackman and Pershing Square Capital Management’s investment in the consumer products giant. Analysts suggest the activist investor may push to replace CEO Bob McDonald and divest non-core brands.
Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.
David Einhorn’s questions during Herbalife’s Q1 earnings call sowed market doubt about the firm, whose stock dropped about 20% May 1. But analysts called the panic behind the sell-off “unwarranted” given the firm’s strong Q1 performance and sound fundamentals.